Switch theme
Sign up to access all valuation multiples
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.
2013
23
LTM Revenue $5.3M
LTM EBITDA n/a
$10.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aelis Farma has a last 12-month revenue of $5.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aelis Farma achieved revenue of $9.7M and an EBITDA of -$4.9M.
Aelis Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aelis Farma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.1M | $9.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$15.2M | -$4.9M | XXX | XXX | XXX |
| EBITDA Margin | -370% | -51% | XXX | XXX | XXX |
| Net Profit | $0.6M | -$15.3M | XXX | XXX | XXX |
| Net Margin | 15% | -158% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Aelis Farma's stock price is EUR 1 (or $1).
Aelis Farma has current market cap of EUR 17.0M (or $18.3M), and EV of EUR 9.5M (or $10.2M).
See Aelis Farma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.2M | $18.3M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Aelis Farma has market cap of $18.3M and EV of $10.2M.
Aelis Farma's trades at 1.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aelis Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aelis Farma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.2M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | XXX | XXX |
| P/E | -3.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAelis Farma's NTM/LTM revenue growth is 20%
Aelis Farma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Aelis Farma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aelis Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aelis Farma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 138% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -51% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 179% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 171% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aelis Farma acquired XXX companies to date.
Last acquisition by Aelis Farma was XXXXXXXX, XXXXX XXXXX XXXXXX . Aelis Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aelis Farma founded? | Aelis Farma was founded in 2013. |
| Where is Aelis Farma headquartered? | Aelis Farma is headquartered in France. |
| How many employees does Aelis Farma have? | As of today, Aelis Farma has 23 employees. |
| Who is the CEO of Aelis Farma? | Aelis Farma's CEO is Mr. Pier Vincenzo Piazza. |
| Is Aelis Farma publicy listed? | Yes, Aelis Farma is a public company listed on PAR. |
| What is the stock symbol of Aelis Farma? | Aelis Farma trades under AELIS ticker. |
| When did Aelis Farma go public? | Aelis Farma went public in 2022. |
| Who are competitors of Aelis Farma? | Similar companies to Aelis Farma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aelis Farma? | Aelis Farma's current market cap is $18.3M |
| What is the current revenue of Aelis Farma? | Aelis Farma's last 12-month revenue is $5.3M. |
| What is the current EV/Revenue multiple of Aelis Farma? | Current revenue multiple of Aelis Farma is 1.9x. |
| What is the current revenue growth of Aelis Farma? | Aelis Farma revenue growth between 2023 and 2024 was 138%. |
| Is Aelis Farma profitable? | Yes, Aelis Farma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
